Martin Shkreli

Former Turing Pharmaceuticals CEO Martin Shrkeli has refused to comply with a subpoena to testify in front of a Senate panel, which convenes next week to discuss drug prices, ArsTechnica reports. It's likely Shkreli also won't appear before a House committee investigation, given his...

Martin Shkreli put up his $45 million E*Trade Financial Corp (NASDAQ: ETFC)account to secure his $5 million bail, according to a filing released Thursday. The former biopharma executive was ordered to disclose how the $5 million bond was secured. "E*Trade has been ordered to notify...

KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) disclosed on Thursday it received a new letter from the Nasdaq exchange on Wednesday. According to KaloBios, the letter from Nasdaq stated that the company's filing for bankruptcy under Chapter 11 constitutes a "separate and additional basis for delisting...

While a company's financials may be one of the most important factors when it comes to making investment decisions, the person at the helm can make or break a firm's image in the public eye. This year, the private sector was full of scandals, crises and high-stakes decisions that cast the...

Short-term trading is an important part of finance and it’s the business of Nadex. But short-term business models are horrible for investors, businesses, and the economy. The arrest of Pharma CEO Martin Shkreli is just a grotesque example of a wider problem. Short-term trading, buying and...

Shares of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) have been halted since the company's controversial CEO Martin Shkreli was arrested on fraud charges on December 17. KaloBios has since fired Shkreli and on Monday appealed a decision by the Nasdaq exchange to delist its shares. In the...

KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) is likely to trade on the 'Grey Market' and not one of the OTC markets since it has been halted, according to an OTC Markets Spokesperson. The company reported that on December 18, 2015, it received a letter from the Nasdaq Listing...

Since 1998, there have been several so-called tops in the market. Each one has been characterized by a specific event, sector or sometimes linked to an individual issue; For the sake of this article, an individual person. A Timeline In 1998, the unwinding of Long-Term Capital Management's...

Hedge fund manager and biopharma CEO Martin Shkreli was arrested Thursday, charged with securities fraud relating to his time as CEO of Retrophin Inc (NASDAQ: RTRX), a company he founded. "Prosecutors charged [Shkreli] with illegally taking stock from Retrophin Inc., a biotechnology firm...

The most unpopular man in the pharmaceutical world is in a little bit of trouble. Turing Pharmaceuticals founder Martin Shkreli has been arrested on securities fraud related to a firm he founded, Bloomberg reported Thursday morning. Separately, Reuters citing witness said the entrepreneur...

The Washington Post, citing a Centers for Disease Control and Prevention study, reported the number of annual HIV diagnoses has dropped by 19 percent between 2005 and 2014. Men who have sex with other men accounted for around 67 percent of all HIV diagnoses in 2014. HIV cases among women fell by...

Martin Shkreli, CEO of Turing Pharmaceuticals, controversially raised the price of a potentially life-saving drug called Daraprim to $750 a pill from $13.50. Express Scripts Holding Company (NASDAQ: ESRX), the largest manager of prescription drug benefits, said on it will now cover a $1 a...

Martin Shkreli has made quite a name for himself over the past couple months. On November 18, he made a 1.2 million share purchase of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO), a biopharma company focused on the development of monoclonal antibody therapeutics. The penny stock company said...

Shares of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) fell around 50 percent on Tuesday. Notable penny trading expert Tim Sykes told New York Post that KaloBios' stock is expected to return to being a penny stock. Martin Shkreli, KaloBios' newly appointed CEO and major stockholder...